Lung Cancer | Specialty

Navigating Treatment Decisions With Immunotherapy in Squamous NSCLC

October 11th 2019

Shiven B. Patel, MD, MBA, FACP, provides insight into key trials in squamous non–small cell lung cancer and how to apply the data to practice.

Emerging Modalities Abound in Stage III NSCLC Treatment

October 11th 2019

William T. Sause, MD, discusses various modalities of stage III non–small cell lung cancer treatment and how to effectively select patients for the varying regimens.

OS Benefit Confirms Osimertinib as Frontline Standard in EGFR+ NSCLC

October 10th 2019

Clarke A. Low, MD, discusses the role of osimertinib in EGFR-mutated non–small cell lung cancer and emerging research efforts in the paradigm.

Novel Drugs Revolutionizing ROS1+ and ALK+ NSCLC

October 10th 2019

Katie Kerrigan, MD, discusses novel agents emerging in both ROS1- and ALK-mutated non–small cell lung cancer and the sequencing challenges for these patients.

Biomarker Discovery Leads to Several Targeted Treatments in NSCLC

October 10th 2019

Wallace L. Akerley, MD, discusses targeted approaches for patients with non-small cell lung cancer who harbor alterations in MET, RET, and HER2, as well as the importance of broad molecular profiling.

New Strategies Generate Optimism for Targeting "Undruggable" KRAS

October 9th 2019

Investigators are starting to make headway in their quest to develop therapies that counteract oncogenic mutations in the KRAS gene, a high-priority target in precision medicine that has long been deemed “undruggable.”

Published Ramucirumab/Erlotinib Data Showcase PFS Benefit in Frontline EGFR+ NSCLC

October 7th 2019

The combination of ramucirumab and erlotinib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus erlotinib alone in treatment-naïve patients with EGFR-mutant non–small cell lung cancer, according to results of the phase III RELAY trial that have now been published in The Lancet Oncology.

Studies Add to Evidence of Utility of Blood-Based Biomarkers in NSCLC

October 7th 2019

Evidence is increasing that blood-based biomarkers have predictive utility in advanced non–small cell lung cancer. Going further, blood-based next-generation sequencing appears to have clinical utility in selecting targeted treatment in this setting.

New Data Establish Long-Term Efficacy for 2 Modern Modalities in NSCLC and Melanoma

October 4th 2019

For nearly a decade, immunotherapy and molecularly targeted agents have been the focus of intense development. Now emerging evidence suggests that both modalities can deliver long-term benefits for patients, but the findings may prompt additional questions of how best to fit these transformative therapies into treatment landscapes.

Entrectinib Delivers Durable Responses in ROS1+, NTRK+ Lung Cancer

October 3rd 2019

Patients with ROS1-positive and NTRK-positive non–small cell lung cancer had frequent and durable responses, which appeared to deepen over time in some cases, with the multikinase inhibitor entrectinib.

Dr. Mudad on RELAY Trial for EGFR-Mutant NSCLC

October 3rd 2019

Raja Mudad, MD, FACP, discusses the RELAY trial and using doublet therapy to treat EGFR-mutant non–small cell lung cancer.

Practice-Changing PACIFIC Trial Opens Road for Immunotherapy in Stage III NSCLC

October 1st 2019

Edgardo S. Santos, MD, FACP, FCCP, discusses data from the PACIFIC trial and how it has changed the standard of care for stage III non–small cell lung cancer patients whose disease has not progressed following concurrent platinum-based chemoradiation.

Genetic Testing Grows as Critical Component in NSCLC Treatment

October 1st 2019

Alberto Chiappori, MD, discusses emerging biomarkers in non–small cell lung cancer and the different ways to test for them.

Pembrolizumab Misses PFS Endpoint in Relapsed Malignant Pleural Mesothelioma

September 30th 2019

Pembrolizumab (Keytruda) did not show an improvement in progression-free survival compared with chemotherapy in patients with malignant pleural mesothelioma.

Atezolizumab Combo Confirmed as Frontline Standard in Advanced Small Cell Lung Cancer

September 29th 2019

With follow-up of nearly 2 years, the addition of atezolizumab to first-line carboplatin plus etoposide for the treatment of extensive stage small cell lung cancer continues to demonstrate improved overall survival compared with placebo plus CP/ET.

ESMO 2019: Dr. Bekaii-Saab Highlights Important Trials in GI Malignancies

September 29th 2019

ESMO 2019: Dr. Mirza on Important Trials with PARP Inhibitors in Ovarian Cancer

September 29th 2019

ESMO 2019: Dr. McGregor Highlights Impactful 2019 Prostate Cancer Studies

September 29th 2019

ESMO 2019: Dr. Spigel Highlights Progress in Lung Cancer

September 29th 2019

ESMO 2019: Dr. Rugo Highlights Progress in Breast Cancer

September 29th 2019